SEP 2 9 2006 Un

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO 09/851614-Conf. #4957 Application Number INFORMATION DISCLOSURE May 8, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Yashwant M. DEO Art Unit 1644 (Use as many sheets as necessary) Examiner Name G. R. Ewoldt Sheet 2 CDJ-166RCE of Attorney Docket Number

	U.S. PATENT DOCUMENTS						
Examine	r Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where		
Initialis*	No 1	Number-Kind Code ² (If known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
13	A1*	US-5,869,057	02-09-1999	Rock	·		
	A2*	US-6,080,409	06-27-2000	Laus et al.			
	A3*	US-6,277,959	08-21-2001	Valladeau et al.			

	FOREIGN PATENT DOCUMENTS							
Exa Initia	miner	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°	
		B1	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation			
		B2	WO-93/04187-A1	03-04-1993	Medical Research Council	1		
L		В3	WO-96/23882-A1	08-08-1996	The Rockefeller University	15.1	1.	
		B4	WO-97/45449-A1	12-04-1997	Hart, Derek et al.	5.		
		B5	WO-99/02562-A1	01-21-1999	Schering Corporation	{:·.	٠.	
Ŀ		B6	WO-99/16455-A1	04-08-1999	The Austin Research Institute	· j	1	
		B7	WO-99/24554-A2	05-20-1999	Univerity of Pittsburgh		11	
		B8	WO-99/47673-A2	09-23-1999	Schering Corporation			
		B9	WO-99/58678-A2	11-18-1999	Micromet GmbH	٧,		
		B10	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College			
		B11,	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.			
_		B12	WO-00/18803-A2	04-06-2000	Schering Corporation			
S	92	B13	WO-01/85798-A2	11-15-2001	Medarex, Inc.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the tFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published and/or country where published.					
BAL	Ç1	Berlyn, Kathleen A. et al, "Generation of Opendritic Cells Armed with PSA/Anti-PSA Immunology, Vol. 101(3):276-283 (2001)	CD4+ and CD8+ T Lymphocyte Responses by (Antigen/Antibody) Complexes," Clinical			
C2 Chien, Nadine C. et al, "Significant structural and functional change of an antigen-binding significant structural mechanism," Proc. Natl. Acad. Sci. USA, Vol. 86:5532-5536 (1989)						
C3 Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresse (CD89), Which Mediates Internalization and Activation Upon Cross-Linkin Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001) C4 Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unrespondence Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (200		nd Activation Upon Cross-Linking by IgA				
		uce Peripheral T Cell Unresponsiveness Under				
	C5		anosomal Proteins in the Immunotherapy of			
xaminer Signature		12/4/16	Date Considered			



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449A/B/P	ro		Complete if Known		
				Application Number	09/851614-Conf. #4957	
11	IFORMATION	IQ ν	SCLOSURE	Filing Date	May 8, 2001	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Yashwant M. DEO	
				Art Unit	1644	
	(Use as many sh	eets a:	s necessary)	Examiner Name	G. R. Ewoldt	
Sheet	2	of	2	Attorney Docket Number	CDJ-166RCE	

		I	Melanoma," Journal of Immunotherapy, Vol. 21(4):237-246 (1998)]
K\$	4/	Æ6	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
		C7	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)	
		C8	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocampatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)	
		C9	Tempest, Philip R. et al, "A Humanized Anti-Tumor Necrosis Factor-\alpha Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	1. (1.1.1)
. •	:	C10	Tjoa, Benjamin et al, "Development of dendritic-cell based prostate cancer vaccine," Immunology Letters, Vol. 74:87-93 (2000)	an Bengari
بيان نا		C11	Tüting, Thomas et al, "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic; F Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th 1-Biasing Cytokines IL-12 and IFN- a1," The Journal of Immunology, Vol. 160:1139-1147 (1998)	staty. Teta e Tabbileo ka iii Tar appraisasi Tar appraisasi
•	-	C12	Wang, Hui et al, "Rapid antibody responses by low-dose, single-step, dendritic cell-targeting immunization," PNAS, Vol. 96(2):847-852 (2000)	
		C13	FRELTA D et al., "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo", International Immunopharmacology, February 2001, vol. 1. 1, no. 2, pages 265-275	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	·
Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English (anguage Translation is attached.